FDA Approves New Immunotherapy for Endometrial Cancer FDA Approves New Immunotherapy for Endometrial Cancer
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair (dMMR).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Media News)
Source: Roche Media News - April 23, 2021 Category: Pharmaceuticals Source Type: news
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Jemperli (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer
London UK 22 April 2021 -- GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company’s Biologics... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 22, 2021 Category: Drugs & Pharmacology Source Type: news
FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Study reveals the 3D structure of human uterine endometrium and adenomyosis tissue
(Niigata University) Recent advances in tissue-clearing-based 3D imaging have permitted researchers to establish a new baseline 3D structure of the endometrial glands, including the formation of a rhizome network in the stratum basalis that expands horizontally along the muscular layer. These findings have implications in understanding the mechanisms underlying normal endometrial tissue processes such as menstruation and fertilized egg implantation, and in clarifying the pathogenesis of endometrium-related diseases, notably adenomyosis, endometriosis, and endometrial cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2021 Category: International Medicine & Public Health Source Type: news
An international study reveals how the 'guardian' of the genome works
(Centro Nacional de Investigaciones Oncol รณ gicas (CNIO)) * Teams from the CNIO, the Leiden University Medical Center and the Netherlands Cancer Institute use electron cryo-electron microscopy to explain how the MutS protein, considered the 'guardian' of the genome, manages to repair the errors that can occur in DNA during cell division* An in-depth understanding of this process is essential to understand how mutations occur that can lead to the development of certain types of tumour, such as Lynch syndrome and endometrial cancer (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 6, 2021 Category: Cancer & Oncology Source Type: news
An IUD Could Ward Off Endometrial Cancer in Women at Risk
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 26, 2021 Category: Cancer & Oncology Tags: Oncology, Obstetrics, News, Source Type: news
An IUD Could Ward Off Endometrial Cancer in Women at Risk
FRIDAY, March 26, 2021 -- For some patients who have early endometrial cancer or a precancerous condition, a hysterectomy may not be a good option because of serious health issues or the desire to preserve fertility.
Now, a new Australian study has... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 26, 2021 Category: General Medicine Source Type: news
An IUD Could Ward Off Endometrial Cancer in Women at Risk
Title: An IUD Could Ward Off Endometrial Cancer in Women at RiskCategory: Health NewsCreated: 3/26/2021 12:00:00 AMLast Editorial Review: 3/26/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 26, 2021 Category: Cancer & Oncology Source Type: news
Endometrial cancer: Patient reduced her thickened endometrial lining naturally
ENDOMETRIAL cancer begins in the uterus - part of the female reproductive system - which the NHS regards as "common", as there are over 9,400 cases each year in the UK. Do you know the warning signs? (Source: Daily Express - Health)
Source: Daily Express - Health - March 21, 2021 Category: Consumer Health News Source Type: news
Estrogen receptor tied to outcomes in DCIS
The estrogen receptor plays a key role in predicting long-term outcomes in patient...Read more on AuntMinnie.comRelated Reading:
SNMMI confirms Medicare reimbursement error for Cerianna
PET aids in treatment of metastatic breast cancer patients
SNMMI, Zionexa call out CMS for reimbursement error
Black women die more frequently from breast cancer
AI tool beats traditional breast cancer risk assessments
FES-PET could predict endometrial cancer outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 16, 2021 Category: Radiology Source Type: news
EU Green Light for Dostarlimab in Some Endometrial Cancers EU Green Light for Dostarlimab in Some Endometrial Cancers
A new PD-1 antagonist, dostarlimab, has been recommended for approval for use in some women with advanced/recurrent endometrial cancer.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Sentinel lymph node mapping best approach to guide adjuvant therapy in endometrial cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news
Study shows new treatment pathway to prevent and treat endometrial cancer recurrence
(Yale University) In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2021 Category: Cancer & Oncology Source Type: news
